Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

Gilbert Bensimon, Albert Ludolph, Yves Agid, Marie Vidailhet, Christine Payan, P Nigel Leigh, NNIPPS Study Group

Abstract

Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and Natural History in Parkinson Plus Syndromes). We analysed the accuracy of our clinical diagnostic criteria, and studied prognostic factors for survival. Patients with an akinetic-rigid syndrome diagnosed as having PSP or MSA according to modified consensus diagnostic criteria were considered for inclusion. The psychometric validity (convergent and predictive) of the NNIPPS diagnostic criteria were tested prospectively by clinical and pathological assessments. The study was powered to detect a 40% decrease in relative risk of death within PSP or MSA strata. Patients were randomized to riluzole or matched placebo daily and followed up to 36 months. The primary endpoint was survival. Secondary efficacy outcomes were rates of disease progression assessed by functional measures. A total of 767 patients were randomized and 760 qualified for the Intent to Treat (ITT) analysis, stratified at entry as PSP (362 patients) or MSA (398 patients). Median follow-up was 1095 days (range 249-1095). During the study, 342 patients died and 112 brains were examined for pathology. NNIPPS diagnostic criteria showed for both PSP and MSA excellent convergent validity with the investigators' assessment of diagnostic probability (point-biserial correlation: MSA r(pb) = 0.93, P < 0.0001; PSP, r(pb) = 0.95, P < 0.0001), and excellent predictive validity against histopathology [sensitivity and specificity (95% CI) for PSP 0.95 (0.88-0.98) and 0.84 (0.77-0.87); and for MSA 0.96 (0.88-0.99) and 0.91 (0.86-0.93)]. There was no evidence of a drug effect on survival in the PSP or MSA strata (3 year Kaplan-Meier estimates PSP-riluzole: 0.51, PSP-placebo: 0.50; MSA-riluzole: 0.53, MSA-placebo: 0.58; P = 0.66 and P = 0.48 by the log-rank test, respectively), or in the population as a whole (P = 0.42, by the stratified-log-rank test). Likewise, rate of progression was similar in both treatment groups. There were no unexpected adverse effects of riluzole, and no significant safety concerns. Riluzole did not have a significant effect on survival or rate of functional deterioration in PSP or MSA, although the study reached over 80% power to detect the hypothesized drug effect within strata. The NNIPPS diagnostic criteria were consistent and valid. They can be used to distinguish between PSP and MSA with high accuracy, and should facilitate research into these conditions relatively early in their evolution.

Trial registration: ClinicalTrials.gov NCT00211224.

Figures

Fig. 1
Fig. 1
Trial Flow Chart. At the selection stage, patients were assigned to either the MSA or PSP strata according to the NNIPPS diagnostic criteria. Following Inclusion, patients within each stratum were randomly allocated to either the riluzole or placebo group on 1:1 ratio and followed-up 3 monthly for 36 months in double-blind fashion. Arrows indicate the time of each assessment.
Fig. 2
Fig. 2
NNIPPS populations in analyses.
Fig. 3
Fig. 3
Kaplan–Meier survival curves of riluzole and placebo groups in PSP and MSA strata.
Fig. 4
Fig. 4
Convergent validity of NNIPPS Diagnostic Criteria with Investigators’ Diagnostic Probability (VAS). At the inclusion visit, following patients’ assignment to strata using the NNIPPS diagnostic criteria, investigators were asked to evaluate the probability of each diagnosis (PSP, MSA), using a 100 mm VAS. All 760 patients are plotted on the graph according to the probability score on each VAS (PSP-vertical axis, MSA-horizontal axis). Solid diamonds represent patients included in the PSP stratum; White circles represent patients included in the MSA stratum. Convergent validity of the NNIPPS inclusion criteria with the investigators’ assessment of diagnostic probability was tested with the point-biserial correlation. MSA, rpb = 0.93 (P < 0.0001), PSP, rpb = 0.95, (P < 0.0001).
Fig. 5
Fig. 5
Syndrome profile of patients in PSP and MSA Strata. At the inclusion visit, and based on the clinical neurological assessments, investigators were asked to describe the syndrome profile of the patients using a systematic (yes/no) questionnaire. Each bar represents the percentage of patients within each stratum positive for a given syndrome. Black bars represent the MSA stratum, grey bars the PSP stratum. The akinetic rigid syndrome was a mandatory inclusion criterion for both strata and therefore is not represented.

References

    1. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci. 2001;24:347–53.
    1. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 1992;42:733–8.
    1. Allison P. Survival Analysis using the SAS System – A Practical Guide. SAS Institute Inc.; 1995.
    1. American Psychological Association. Standard for educational and psychological testing. Washington DC: American Psychological Association ed.; 1985.
    1. Attia J. Moving beyond sensitivity and specificity: Using likelihood ratios to help interpret diagnostic tests. Australian Prescriber. 2003;26:111–13.
    1. Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology. 1997;48:384–93.
    1. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249:609–15.
    1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
    1. Berciano J, Boesch S, Pérez-Ramos JM, Wenning GK. Olivopontocerebellar atrophy: toward a better nosological definition. Mov Disord. 2006;21:1607–13.
    1. Bishop Y, Fienberg S, Holland P. Discrete multivariate analysis: theory and practice. Cambridge, MA: MIT Press; 1975.
    1. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology. 1997;49:1284–8.
    1. Burk K, Daum I, Rub U. Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord. 2006;21:772–6.
    1. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol. 2002;1:359–69.
    1. Caumont AS, Octave JN, Hermans E. Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells. J Neurochem. 2006;97:128–39.
    1. Cox D. Regression models and life tables. J R Stat Soc. 1972;B34:187–220.
    1. Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246(Suppl. 2):II6–15.
    1. Dickson DW, Rademakers R, Hutton ML. Progressive supranuclear palsy: pathology and genetics. Brain Pathol. 2007;17:74–82.
    1. Diguet E, Fernagut PO, Scherfler C, Wenning G, Tison F. Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. J Neural Transm. 2005;112:613–31.
    1. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther. 1999;81:163–221.
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
    1. Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, et al. The European Multiple System Atrophy-Study Group (EMSA-SG) J Neural Transm. 2005;112:1677–86.
    1. Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG) Mov Disord. 2006;21:179–86.
    1. Gilman S, Little R, Johanns J, Heumann M, Kluin KJ, Junck L, et al. Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology. 2000;55:527–32.
    1. Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler C, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res. 1998;8:359–62.
    1. Gilman S, Quinn NP. The relationship of multiple system atrophy to sporadic olivopontocerebellar atrophy and other forms of idiopathic late-onset cerebellar atrophy. Neurology. 1996;46:1197–9.
    1. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology. 1988;38:1031–4.
    1. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130:1552–65.
    1. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy) Neurology. 1994;44:2015–19.
    1. Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S, et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci USA. 2002;99(Suppl. 4):16400–6.
    1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–42.
    1. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–31.
    1. Landwehrmeyer GB, Dubois B, de Yebenes JG, Kremer B, Gaus W, Kraus PH, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol. 2007;62:262–72.
    1. Lantos PL, Papp MI. Cellular pathology of multiple system atrophy: a review. J Neurol Neurosurg Psychiatry. 1994;57:129–33.
    1. Litvan I. Update on epidemiological aspects of progressive supranuclear palsy. Mov Disord. 2003;18(Suppl. 6):S43–50.
    1. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996a;47:1–9.
    1. Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) Neurology. 1996b;46:922–30.
    1. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467–86.
    1. Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol. 1997;54:937–44.
    1. Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996c;55:97–105.
    1. Litvan I, Hutton M. Clinical and genetic aspects of progressive supranuclear palsy. J Geriatr Psychiatry Neurol. 1998;11:107–14.
    1. Litvan I, Lees AJ. Progressive supranuclear palsy. Adv Neurol. 1999;80:341–5.
    1. Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996d;60:615–20.
    1. Lyoo CH, Jeong Y, Ryu YH, Lee SY, Song TJ, Lee JH, et al. Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain. 2008;131:438–46.
    1. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1958;22:719–48.
    1. Mattson MP. Excitotoxic and excitoprotective mechanisms: Abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med. 2003;3:65–94.
    1. Meininger V. Clinical trials in ALS: what did we learn from recent trials in humans? Neurodegener Dis. 2005;2:208–14.
    1. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2007;CD001447
    1. Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research. J Neurol Sci. 1999;169:2–12.
    1. Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology. 2003;60:910–16.
    1. Nath U, Ben-Shlomo Y, Thomson RG, Morris HR, Wood NW, Lees AJ, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain. 2001;124:1438–49.
    1. Nath U, Burn DJ. The epidemiology of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) Parkinsonism Relat Disord. 2000;6:145–53.
    1. Nunnally J, Bernstein I. Psychometric theory. New York: McGraw-Hill, Inc; 1994.
    1. Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord. 2004;19:181–9.
    1. Osaki Y, Ben-Shlomo Y, Wenning GK, Daniel SE, Hughes A, Lees AJ, et al. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology. 2002;59:1486–91.
    1. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) J Neurol Sci. 1989;94:79–100.
    1. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord. 2005;11(Suppl. 1):S3–7.
    1. Robbins TW, James M, Lange KW, Owen AM, Quinn NP, Marsden CD. Cognitive performance in multiple system atrophy. Brain. 1992;115:271–91.
    1. Robbins TW, James M, Owen AM, Lange KW, Lees AJ, Leigh PN, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry. 1994;57:79–88.
    1. Santacruz P, Uttl B, Litvan I, Grafman J. Progressive supranuclear palsy: a survey of the disease course. Neurology. 1998;50:1637–47.
    1. Scherfler C, Sather T, Diguet E, Stefanova N, Puschban Z, Tison F, et al. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy) J Neural Transm. 2005;112:1025–33.
    1. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354:1771–5.
    1. Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. Mov Disord. 2008;23:294–6.
    1. Shortland PJ, Leinster VH, White W, Robson LG. Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro. Eur J Neurosci. 2006;24:3343–53.
    1. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2000;920:16–27.
    1. Streiner D, Norman G. Health Measurement Scales: a practical guide to their development and use. Oxford: Oxford University Press; 2003.
    1. Testa D, Filippini G, Farinotti M, Palazzini E, Caraceni T. Survival in multiple system atrophy: a study of prognostic factors in 59 cases. J Neurol. 1996;243:401–4.
    1. Testa D, Monza D, Ferrarini M, Soliveri P, Girotti F, Filippini G. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci. 2001;22:247–51.
    1. Vanacore N, Bonifati V, Colosimo C, Fabbrini G, De Michele G, Marconi R, et al. Epidemiology of progressive supranuclear palsy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci. 2001b;22:101–3.
    1. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, De Michele G, Marconi R, et al. Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci. 2001a;22:97–9.
    1. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125:1070–83.
    1. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain. 2005;128:1247–58.
    1. Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain. 2007;130:1566–76.
    1. Winer B. Design and analysis of factorial experiments in Statistical principles in experimental design. New York: McGraw-Hill Inc; 1971. pp. 309–430.
    1. Wu MC. Sample size for comparison of changes in the presence of right censoring caused by death, withdrawal, and staggered entry. Control Clin Trials. 1988;9:32–46.
    1. Wu MC, Bailey K. Analysing changes in the presence of informative right censoring caused by death and withdrawal. Stat Med. 1988;7:337–46.
    1. Yoo MH, Hyun HJ, Koh JY, Yoon YH. Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Invest Ophthalmol Vis Sci. 2005;46:4780–7.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren